

TABLE OF CONTENTS

	Page
Title Page	i
Declaration	ii
Dedications	iii
Presentations at Conferences	iv
List of Contributors	v
Acknowledgements	vi
Abstract	vii
Table of Contents	ix
List of Figures	xvi
List of Tables	xviii
Abbreviations	xx
CHAPTER 1: INTRODUCTION	1
1.1 HIV/AIDS pandemic	1
1.2 Natural history of HIV-1 infection	2
1.3 Serology of HIV-1 infection	5
1.4 Virus structure	7
1.5 Cellular tropism and interaction of HIV-1 with co-receptor molecules	8
1.6 HIV-1 genomic organization	10
1.7 Classification of HIV-1	10
1.8 The HIV-1 envelope structure	11
1.9 Blocking viral entry	14
1.9.1 Reagents preventing gp120:CD4 interactions	14
1.9.2 CCR5 and CXCR4 inhibitors	15
1.9.3 Fusion inhibitor	15
1.9.4 Monoclonal antibodies to co-receptors	16
1.10 Characteristic features of antibodies	16
1.10.1 Structure of antibody	16
1.10.2 Functions of antibodies	19

1.11	T-helper cells	21
1.12	Clonal selection and B-cell development	22
1.13	Organization of immunoglobulin gene and generation of diversity	25
1.14	Intrachain amplification of diversity	27
1.15	Interchain amplification of diversity	28
1.16	Somatic hypermutation	28
1.17	HIV-1 envelope glycoprotein as a target for immune response	29
	1.17.1 Glycosylation as a means to evade immune surveillance	29
	1.17.2 Structural elements of gp120	31
	1.17.3 HIV-1 Nab response	32
	1.17.3.1 CD4BS mAbs	33
	1.17.3.2 CD4i mAbs	34
	1.17.3.3 2G12 mAb	34
	1.17.3.4 IgG1b12 mAb	35
	1.17.3.5 Soluble CD4-1.7B	36
	1.17.3.6 Other selected mAbs	37
	1.17.3.7 Anti-V3 antibodies	38
	1.17.4 Epitopes of gp41	40
	1.17.4.1 2F5 mAb	40
	1.17.4.2 4E10 and Z13 mAbs	42
1.18	Viral neutralization	42
	1.18.1 TCLA versus primary virus neutralization	42
	1.18.2 Mechanisms of neutralization	43
	1.18.3 Neutralization escape	46
1.19	Passive immunization and treatment	47
	1.19.1 Treatment	47
	1.19.2 Passive immunization	48
1.20	Vaccine strategies	49
	1.20.1 Role of neutralizing antibodies	49
	1.20.2 Creating vaccine immunogens	51
	1.20.3 Existing vaccines	53

1.21	Approaches to generate mAbs	54
1.21.1	EBV immortalization of human B-cells	54
1.21.2	Cell fusion	57
1.21.3	Phage display technologies	57
1.22	Study background	58
1.23	Study objectives	59
 CHAPTER 2: MATERIALS AND METHODS		 61
2.1	Source of PBMC for EBV-transformation	61
2.2	Monoclonal antibodies	63
2.2.1	mAbs used in screening	63
2.2.2	Additional mAbs used in analysis	63
2.2.3	Production of antibodies from cell lines	65
2.2.4	Purification of mAbs	65
2.2.5	Determination of protein concentration	66
2.2.6	Biotinylation of mAbs	67
2.3	Preparation of macrophage feeders	68
2.3.1	Properties of macrophages	68
2.3.2	Production of GM-CSF	68
2.3.3	Culturing and harvesting of macrophage feeders	69
2.3.4	Irradiation and seeding of feeders	70
2.4	Making antigen preparations	70
2.4.1	Sources of subtype B antigens	70
2.4.2	Generating antigen preparations from HIV-1 subtype C viruses	71
2.4.2.1	Viruses	71
2.4.2.2	Cell lines	72
2.4.2.3	Infection of cell lines	73
2.4.2.4	Determination of p24 antigen levels	74
2.4.2.5	Making viral lysates	75
2.4.2.6	Evaluating antigen stocks	75
2.4.2.7	Use of antigen stock	77

2.5	Production of soluble CD4 using CHO cell lines	77
2.6	Production of EBV	78
2.7	Transformation of B-cells using EBV	78
2.8	Screening and subcloning of transformation cultures	79
	2.8.1 Determination of IgG content (primary cultures)	79
	2.8.2 Screening for anti-HIV-1⁺ specific antibodies (primary cultures)	80
	2.8.3 Sub-culturing of anti-HIV-1⁺ wells (secondary cultures)	81
	2.8.4 Selecting cell lines producing anti-HIV-1 antibodies (tertiary cultures)	82
2.9	Expansion of HIV-1 clones and productions of antibodies	83
2.10	Purification and biotinylation of Du23 mAbs	84
2.11	Generation of HIV-1 subtype C envelope glycoproteins	84
	2.11.1 Plasmid DNA	84
	2.11.2 Propagation of plasmid DNA	85
	2.11.3 Primers used in PCR	86
	2.11.4 Transient expression of HIV-1 Env glycoprotein from Du151 gp150	87
	2.11.5 Mutagenesis	87
	2.11.5.1 Deletion of C1 region	88
	2.11.5.2 Restriction analysis of deleted C1 region	90
	2.11.5.3 Deletion of V1/V2 region	91
	2.11.5.4 Restriction analysis of deleted V1/V2 region	92
2.12	Immunoprecipitation	92
2.13	Characterization of Du23 mAbs	93
	2.13.1 Determination of IgG subclass	93
	2.13.2 Determination of IgG light chain	93
	2.13.3 Western blotting	93
	2.13.3.1 SDS-PAGE	93
	2.13.3.2 Transfer of protein from gel to membrane	94

2.13.4	Antibody binding assays	95
2.13.4.1	Binding Du23 mAbs to viral antigen stock	95
2.13.4.2	Cross-competition assays	95
2.13.4.2.1	Direct capture ELISA	96
2.13.4.2.2	Reverse capture ELISA	97
2.13.5	Testing the dependence of Du23 mAbs on protein conformation	97
2.13.6	Neutralization assays	98
2.13.6.1	Viruses	98
2.13.6.2	Luciferase assay	99
2.13.6.2.1	Evaluating virus titres	99
2.13.6.2.2	Neutralization using cell line grown viruses	99
2.13.6.2.3	Neutralization using pseudovirions	100
CHAPTER 3:	RESULTS	101
3.1	Evaluation of the antigen stock used in screening	101
3.2	Transformation of HIV-1-specific B cells	103
3.2.1	Transformation efficiencies	103
3.2.2	EBV-transformation and cloning process using PBMC from Du23	104
3.3	Purification and evaluations of purity of Du23 mAbs	107
3.4	Determination of protein concentration of Du23 mAbs	108
3.5	Characteristic features of the Du23 mAbs	110
3.5.1	Isotype and subclass determination	110
3.5.2	Binding specificity	110
3.5.2.1	Ability of Du23 mAbs to bind to Env glycoproteins from different strains	110
3.5.2.2	Cross-competition ELISA using Du151 gp150 protein	113
3.5.2.3	Western blots	113
3.5.3	Testing the dependence of Du23 mAbs on conformation of proteins	115
3.5.4	Competition of Du23 mAbs and assessing the effect of sCD4	117
3.5.5	Reverse capture cross-competition analysis of Du23 mAbs	120
3.5.6	Direct capture cross-competition using EH21 (N-terminus) mAb	122

3.5.7	Reverse capture cross-competition using Yu-2 gp120 protein	123
3.5.9	Reverse capture cross-competition using Du179/STR5 antigens	125
3.5.10	Mutagenesis	126
3.5.10.1	Binding of Du23 mAbs to wild-type envelope proteins	126
3.5.10.2	Restriction analysis of V1/V2 deletion	127
3.5.10.3	Restriction analysis of C1 deletion	128
3.5.10.4	Binding of Du23 mAbs to V1/V2 deleted protein	131
3.5.10.5	Binding of Du23 mAbs to C1 deleted protein	132
3.5.11	Assessment of Du23 mAbs for neutralization activity	133
3.5.11.1	Determination of titres for Du179/STR5 and Du151/STR5 viruses	133
3.5.11.2	Determination of titres for other subtype C viruses	135
3.5.11.3	Neutralization assay using cell line grown viruses	137
3.5.11.4	Neutralization assay using pseudovirions	140
CHAPTER 4: DISCUSSION		141
4.1	Importance of the quality of antigen preparations	141
4.2	Making human monoclonal antibodies	142
4.3	Difficulties in making mAbs	143
4.4	Characterization of Du23 mAbs	146
4.4.1	Subclass, purity and specificity	146
4.4.2	Determining viral subtype restriction on binding of Du23 mAbs	147
4.4.3	Reaction of clones to reduced and non-reduced gp120 proteins	148
4.4.4	Epitope mapping	148
4.4.4.1	Mutagenesis approach	148
4.4.4.2	Competition analysis	150
4.4.4.3	Effect of sCD4	154
4.4.5	Neutralization	154

CHAPTER 5:	CONCLUDING REMARKS	158
5.1	Current immunogens	158
5.2	Other uses of mAbs	160
5.3	Future work	161
CHAPTER 6:	REFERENCES	164
CHAPTER 7:	APPENDICES	185
7.1	Ethics certificates	185
	7.1.1 Generating antibody-secreting B cell lines	185
	7.1.2 Isolation, characterization and neutralization of viruses	186
7.2	pcDNA3.1 plasmid map	187
7.3	Solutions, Buffers and Reagents	188
7.4	Culture media	188
7.5	Antibiotics	189
7.6	Other Reagents	189
7.7	List of suppliers	191

LIST OF FIGURES	PAGE
	3
Figure 1. Lymphatic tissue reservoirs for HIV-1 and the potential obstacles the immune system faces in clearing the virus.	
Figure 2. Serological profile of HIV-1 infection in humans.	6
Figure 3. Diagram showing HIV-1 structure.	8
Figure 4. Structure of HIV-1 gp120 core.	13
Figure 5. Diagram showing the basic structure of an IgG antibody.	18
Figure 6. Diagrammatic representation of B-cell developmental pathways.	23
Figure 7. Organization of immunoglobulin genes.	26
Figure 8. Immunological diagram representing monomeric gp120 core structure based on X-ray crystal structure of HIV-1 HXBc2 gp120 core complexed with CD4 and 1.7B.	32
Figure 9. The core structure of gp120 indicating the binding sites for selected neutralizing antibodies.	36
Figure 10. Schematic representation of gp41 structure.	41
Figure 11. Diagram showing the main procedures used in cloning.	83
Figure 12. Schematic representation of the principles of the QuickChange site directed mutagenesis method.	88
Figure 13. Diagram showing the positions of primers in Du151 gp150 used to generate mutants.	90
Figure 14. Diagram showing two main ELISA formats used in analysis of Du23 mAbs.	96
Figure 15. Graph showing evaluation of representative antigen preparations of Du151 and Du179 grown in STR5, D3R5 and MTR5 cell lines and used in screening for Du23 mAbs.	102
Figure 16. Coomassie stain of polyacrylamide gel electrophoresis of purified Du23 mAbs.	107

Figure 17. Standard curve used to determine the concentration of representative samples of the Du23 mAbs.	108
Figure 18. Representative results showing the ability of Du23 mAbs to bind ADA, Yu-2 gp120, 89.6 and Du179 grown in STR5 cells.	111
Figure 19. Western blot analysis of Du23 mAbs binding to recombinant Du151 gp150 envelope protein.	114
Figure 20. Graph showing the effect of protein/antigen denaturation on binding of the Du23 mAbs.	116
Figure 21. Graph showing the ability of unlabeled Du23 mAbs to compete with biotinylated mAbs of known specificities and assessing the effect of sCD4 on binding.	119
Figure 22. Assessing the ability of the Du23 mAbs to bind to Du151 gp150 proteins.	126
Figure 23. 1% agarose gel-electrophoresis of restriction analyses of cloned Du151 gp150 DNA after the V1/V2 regions were deleted.	128
Figure 24. 1% agarose gel-electrophoresis of restriction analysis of cloned Du151 gp150 DNA after C1 region has been deleted.	130
Figure 25. Binding of Du23 mAbs to Du151 gp150 protein after V1/V2 regions have been deleted.	132
Figure 26. Binding of Du23 mAbs to Du151 gp150 protein with deleted C1 region.	133
Figure 27. Graph showing titers of subtype C viruses using JC53 cells in luciferase assay.	135
Figure 28. Determining the titres of viral isolates using JC53 cell line.	136
Figure 29. Neutralization of subtype C viral strains using Du23 mAbs, in luciferase assay and JC53 cells.	138

LIST OF TABLES	PAGE
Table 1. Patient information from whom PBMC samples used for EBV-transformations were derived.	62
Table 2. Properties of mAbs used as tools in screening and analysis processes.	64
Table 3. Subtype B viruses used to generate antigen preparations.	71
Table 4. Subtype C viral isolates used to infect various cell lines to make antigens used for screening transformation cultures.	72
Table 5. Summary of characteristic features of cell lines used in various experiments.	73
Table 6. Reverse and forward primers used for deleting C1 or V1V2 regions.	86
Table 7. Summary of EBV-immortalization yields and efficiencies for making monoclonal antibodies to HIV-1 envelope glycoproteins.	104
Table 8. Results of the procedure used to produce human mAbs to HIV-1 from PBMC derived from Du23 sample.	106
Table 9. Determination of the concentration of a representative samples of the Du23 mAbs.	109
Table 10. Summary of binding ability of Du23 mAbs to various antigen preparations.	112
Table 11. Summary of the characteristic features of the Du23 mAbs.	114
Table 12. Competition of Du23 mAbs against various mAbs of known specificity	121
Table 13. Competition of Du23 mAbs against various mAbs of known specificities using EH21 as capture and Du151 gp150	123
Table 14. Competition of Du23 mAbs with a panel of mAbs of known specificities using purified Yu-2 gp120	124
Table 15. Competition of Du23 mAbs against various defined mAbs using Du179/STR5 antigens.	125

Table 16. Summary of neutralization experiments.	139
Table 17. Evaluation of neutralization activity of Du23 mAbs using Du151 pseudovirions.	140
Table 18. Summary of the cross-competition analysis of the Du23 mAbs.	153

ABBREVIATIONS

1	Ab	Antibody
2	Ag	Antigen
3	AIDS	Acquired immunodeficiency syndrome
4	ATP	Adenosine triphosphate
5	B-cells	Bursa-cells (ontological origin from the bursa of marrow)
6	BCR	B-cell receptor
7	bp	Base pair
8	BSA	Bovine serum albumin
9	C1-5	Constant regions 1-5
10	CCR5	Cysteine-to-cysteine (C-C) receptor 5
11	CD4bs	CD4 binding site
12	CD4i	CD4 induced
13	CDR	Complementarity determining region
14	CR (2)	Complement receptor (2)
15	CXCR4	C-C and X is (any other) intervening amino acid receptor (4)
16	CO ₂	Carbon dioxide
17	°C	Degree celcius
18	DMSO	Dimethylsulfoxide
19	DNA	Dioxyribonucleic acid
20	dNTP	Dideoxyribonucleoside triphosphate
21	DTT	Dithitreitol
22	EBER	EBV-encoded RNAs
23	EBNA	EBV Nuclear antigens
24	EBV	Epstein-Barr virus
25	EBNA	Epstein Barr virus nuclear antigen
26	EDTA	Ethylenediaminetetraacetic acid
27	ELISA	Enzyme-linked immunosorbent assay
28	<i>env</i>	Envelope gene
29	Env	Envelope protein

30	FCS/FBS	Fetal calf/bovine serum
31	<i>gag</i>	Group associated antigens gene
32	Gag	Group associate antigens protein
33	GCT	Giant cell tumor
34	gp120	Glycoprotein 120
35	GPGQ	Glycine, proline, glycine, and glutamine amino acids
36	HBSS	Hank's balance salt solution
37	H-CDR3	Heavy chain third complementarity-determining region
38	h-IgG	Human-IgG
39	h-GM-CSF	Human granulocyte-macrophage colony stimulation factor
40	HIV-1	Human immunodeficiency virus type 1
41	HPO-SA	Horseradish peroxidase coupled to strepavidine
42	H ₂ O	Water
43	IgG	Immunoglobulin G
44	IL-2	Interleukin-2 (and others)
45	LB	Luria broth
46	LMP	Latent membrane protein
47	LTNP	Long-tern nonprogressor
48	LTR	Long terminal repeat
49	M-group	Major group
50	μl	Microlitre
51	μm	Micrometre
52	μg/ml	Micrograms per millilitre
53	mAb	Monoclonal antibody
54	ml	Millilitre
55	mg/ml	Milligrams per millilitre
56	MgCl ₂	Magnesium chloride
57	mM	Millimolar
58	NaCl	Sodium chloride
59	ND	Not done
60	ng/ml	Nanogram per millilitre

61	N group	Novel variant
62	NF κ B	Nuclear factor- κ B
63	NSI	Non-syncytium inducing
64	OD _{450nm}	Optical Density at 450 nanometer
65	O group	Outlier group
66	PBMC	Peripheral blood mononuclear cell
67	PBS	Phosphate buffered saline
68	PCR	Polymerase chain reaction
69	R5	CCR5 using viruses
70	RANTES	Regulated on activation normal T-cell expressed and activated
71	RNA	Ribonucleic acid
72	rpm	Revolutions per minute
73	RT	Room temperature
74	SI	Syncytium inducing
75	SIV	Simian immunodeficiency virus
76	TBS	Tris-buffered saline
77	TCID ₅₀	Tissue culture infectious dose-50
78	TEMED	N,N,N,N-tetramethylenediamine
79	TCLA	T-cell line adapted
80	TMB	2,3-Tetra-4-5- methyl benzidine
81	μ g	Microgram
82	U	Unit
83	V1-V5	Variable loops 1-5
84	V _H	Variable heavy (chain of immunoglobulin)
85	V _L	Variable light (chain of immunoglobulin)
86	VDJ	Variable diversification joining regions of immunoglobulin genes
87	V _{λ} DJ _{κ}	Variable(<i>lambda</i>) diversification joining(<i>kappa</i>)
88	WHO	World Health Organization
89	X4	CXCR4 using viruses
90	Kd	Kilo-daltons